Biofrontera Revenue

Biofrontera had revenue of $6.99M in the quarter ending September 30, 2025, a decrease of -22.46%. This brings the company's revenue in the last twelve months to $37.16M, up 5.11% year-over-year. In the year 2024, Biofrontera had annual revenue of $37.32M with 9.54% growth.

Revenue (ttm)

$37.16M

Revenue Growth

+5.11%

P/S Ratio

0.25

Revenue / Employee

$399,613

Employees

Market Cap

9.63M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	37.32M	3.25M	9.54%
Dec 31, 2023	34.07M	5.40M	18.82%
Dec 31, 2022	28.67M	4.57M	18.98%
Dec 31, 2021	24.10M	5.25M	27.86%
Dec 31, 2020	18.85M	-7.33M	-28.01%
Dec 31, 2019	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Aytu BioPharma	62.64M
IM Cannabis	37.61M
Sunshine Biopharma	37.32M
cbdMD	19.09M
Sonoma Pharmaceuticals	17.72M
RedHill Biopharma	9.55M
InMed Pharmaceuticals	4.51M
TherapeuticsMD	2.80M

Revenue Rankings

BFRI News

6 hours ago - Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - GlobeNewsWire
11 days ago - U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable - GlobeNewsWire
20 days ago - Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities - GlobeNewsWire
26 days ago - Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma - GlobeNewsWire
4 weeks ago - Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint - GlobeNewsWire
7 weeks ago - Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth - GlobeNewsWire
2 months ago - Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones - GlobeNewsWire
2 months ago - Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio - GlobeNewsWire

More News